Log in to search using one of your social media accounts:

 

Driving safety and fitness to drive in sleep disorders - Tippin J, Dyken ME.

Driving an automobile while sleepy increases the risk of crash-related injury and death. Neurologists see patients with sleepiness due to obstructive sleep apnea, narcolepsy, and a wide variety of neurologic disorders. When addressing fitness to drive, the...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Related Links:

Authors: Lerousseau L Abstract Excessive daytime sleepiness is a major symptom in cases of the obstructive sleep apnea-hypopnea syndrome. Most often, it is vastly improved by treatment with continuous positive airway pressure (CPAP). The most effective way to confirm its disappearance is through wakefulness maintenance testing. If residual sleepiness remains, despite CPAP, further diagnostic investigation must be carried out. Firstly, it must be assessed whether the treatment is fully effective (apnea hypopnea index6h/night). If this is the case, the possibility of other situations responsible for excessive daytime...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
CONCLUSIONS: Our results suggest that the predictive value of the ESS score in patients with subjective EDS is low and patient subgroup-specific (superior in hypersomnia/narcolepsy vs. other diagnoses) and that the commonly used cut-off of 11 points may be insufficient for clinical practice. PMID: 29340766 [PubMed - as supplied by publisher]
Source: Wiener Klinische Wochenschrift - Category: General Medicine Authors: Tags: Wien Klin Wochenschr Source Type: research
DUBLIN, Dec. 21, 2017 -- (Healthcare Sales &Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing appro... Biopharmaceuticals, FDA Jazz Pharmaceuticals, solriamfetol, narcolepsy, obstructive sleep apnea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Introduction: This phase 3 pivotal trial evaluated solriamfetol, a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, for the treatment of excessive sleepiness (ES) in patients with  obstructive sleep apnea (OSA). ES is a common OSA symptom that can persist and affect activities of daily living despite primary treatment such as continuous positive airway pressure (CPAP) or oral appliances.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
In this study, we examined the association between these three methods and their possible utility as predictors of cardiovascular morbidity by examining their association with preclinical markers of metabolic risk, i.e.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
The objective of this work was to assess the prevalence and the main risk factors for DD.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
Introduction: Excessive sleepiness in patients with obstructive sleep apnea (OSA) is associated with reductions in health-related quality-of-life (HRQoL), impaired functioning at work, and negative impact on daily activities. The efficacy of solriamfetol (JZP-110), a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, was evaluated in a phase 3 study in patients with excessive sleepiness due to OSA.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
Introduction: Excessive sleepiness (ES), a common symptom of obstructive sleep apnea (OSA), can persist despite primary treatment. Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. This phase 3, 6-week, randomized-withdrawal trial evaluated the efficacy of solriamfetol for treatment of ES in OSA.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
Authors: Pelizza P Abstract For a long time, European legislation has not considered the Obstructive Sleep Apnea Syndrome (OSAS) a relevant factor for road safety. In Italy, in 2010 the Scientific Society of Legal Medicine COMLAS published Guidelines for the assessment of fitness to drive. An entire chapter, written in collaboration with the Commission "Sleepiness, Safety and Transportation" of the Italian Association of Sleep Medicine (AIMS), is dedicated to the criteria for assessing fitness to drive of people with OSAS or narcolepsy. Only in 2016, following the adoption of European Commission Directive...
Source: Medicina del Lavoro - Category: Occupational Health Tags: Med Lav Source Type: research
Authors: Ferini-Strambi L, Sforza M, Poletti M, Giarrusso F, Galbiati A Abstract Excessive Daytime Sleepiness (EDS) is a common condition with a significant impact on quality of life and general health. A mild form of sleepiness can be associated with reduced reactivity and modest distractibility symptoms, but more severe symptomatic forms are characterized by an overwhelming and uncontrollable need to sleep, causing sudden sleep attacks, amnesia and automatic behaviors. The prevalence in the general population is between 10 and 25%. Furthermore, EDS has been considered a core symptom of obstructive sleep apnea (OS...
Source: Medicina del Lavoro - Category: Occupational Health Tags: Med Lav Source Type: research
More News: Brain | Narcolepsy | Neurology | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine